Stocks › DGX
QUEST DIAGNOSTICS INC
DGX·NYSE·
United States·USD
$258.28
-0.81 (-0.31%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
DGX
QUEST DIAGNOSTICS INC · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
DGXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of DGX by members of U.S. Congress · 126 on record · 12 in the last 12 months
Whale Activity
Position changes in DGX reported for 2026-09-30 by 1219 institutional filers
- Increased371
- New124
- Held206
- Decreased391
- Closed74
- No prior filing53
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 9.3M | $2.16B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.2M | $1.68B | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.1M | $1.42B | decreased |
| STATE STREET CORP | 5.6M | $1.30B | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.0M | $1.17B | decreased |
| Boston Partners | 4.6M | $1.08B | decreased |
| FMR LLC | 4.5M | $1.05B | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 3.2M | $734.9M | increased |
| JPMORGAN CHASE & CO | 2.9M | $669.9M | decreased |
| MORGAN STANLEY | 2.5M | $575.1M | increased |
| EdgePoint Investment Group Inc. | 2.1M | $488.9M | decreased |
| DIMENSIONAL FUND ADVISORS LP | 2.0M | $466.8M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by DGX insiders, by quarter · Form 4
Recent Insider Transactions
2,086 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Deppe Michael JSVP, Corp. Controller & CAO | Sale | −6,261 | $260.17 | $1.6M | Nov 13, 2026 | Form 4 ↗ |
| Deppe Michael JSVP, Corp. Controller & CAO | Sale | −5,515 | $260.17 | $1.4M | Nov 13, 2026 | Form 4 ↗ |
| Plewman PatrickSVP for Diagnostic Services | Sale | −6,793 | $257.34 | $1.7M | Nov 9, 2026 | Form 4 ↗ |
| Plewman PatrickSVP for Diagnostic Services | Sale | −650 | $257.34 | $167K | Nov 9, 2026 | Form 4 ↗ |
| Plewman PatrickSVP for Diagnostic Services | Sale | −4,274 | $257.34 | $1.1M | Nov 9, 2026 | Form 4 ↗ |
| Doherty Catherine T.Executive Vice President | Sale | −5,990 | $246.26 | $1.5M | Nov 3, 2026 | Form 4 ↗ |
| Doherty Catherine T.Executive Vice President | Sale | −3,818 | $245.45 | $937K | Nov 3, 2026 | Form 4 ↗ |
| Doherty Catherine T.Executive Vice President | Sale | −3,004 | $249.40 | $749K | Nov 3, 2026 | Form 4 ↗ |
| Doherty Catherine T.Executive Vice President | Sale | −2,907 | $251.24 | $730K | Nov 3, 2026 | Form 4 ↗ |
| Doherty Catherine T.Executive Vice President | Sale | −2,877 | $250.49 | $721K | Nov 3, 2026 | Form 4 ↗ |
| Doherty Catherine T.Executive Vice President | Sale | −2,358 | $248.38 | $586K | Nov 3, 2026 | Form 4 ↗ |
| Doherty Catherine T.Executive Vice President | Sale | −1,151 | $246.98 | $284K | Nov 3, 2026 | Form 4 ↗ |
| PFEIFFER GARY MDirector · Director | Sale | −1,203 | $243.00 | $292K | Oct 26, 2026 | Form 4 ↗ |
| Davis J. E.CEO and President · Director | Sale | −10.0K | $242.72 | $2.4M | Sep 1, 2026 | Form 4 ↗ |
| PREVOZNIK MICHAEL ESVP & General Counsel | Gift | −1,000 | $0.00 | $0 | Aug 28, 2026 | Form 4 ↗ |
| PREVOZNIK MICHAEL ESVP & General Counsel | Sale | −430 | $244.51 | $105K | Aug 28, 2026 | Form 4 ↗ |
| PREVOZNIK MICHAEL ESVP & General Counsel | Sale | −6,237 | $243.63 | $1.5M | Aug 28, 2026 | Form 4 ↗ |
| PREVOZNIK MICHAEL ESVP & General Counsel | Sale | −16.0K | $242.88 | $3.9M | Aug 28, 2026 | Form 4 ↗ |
| PREVOZNIK MICHAEL ESVP & General Counsel | Option exercise | +22.7K | $112.17 | $2.5M | Aug 28, 2026 | Form 4 ↗ |
| DELANEY MARK ESVP & Chief Commercial Officer | Sale | −1,600 | $235.18 | $376K | Jul 28, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding DGX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.5M | $744.9M | 0.03% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 2.9M | $607.9M | 0.04% | Jun 30, 2026 |
| VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.4M | $508.4M | 0.23% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 1.4M | $345.3M | 0.04% | Aug 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 1.5M | $322.0M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 1.3M | $284.3M | 0.04% | Jun 30, 2026 |
| Disciplined Value Mid Cap Fund John Hancock Funds III | 1.2M | $259.2M | 1.12% | Jun 30, 2026 |
| JPMorgan Equity Income Fund JPMorgan Trust II | 1.2M | $244.4M | 0.56% | Jun 30, 2026 |
| T. Rowe Price Dividend Growth Fund, Inc. | 1.1M | $235.1M | 0.99% | Jun 30, 2026 |
| Disciplined Value Fund John Hancock Funds III | 1.1M | $225.7M | 1.15% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list DGX's shares (CUSIP 74834L100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming quest diagnostics as client
- FEDERAL STREET STRATEGIES, LLCQUEST DIAGNOSTICS INCORPORATED · 2026 Q3 · HCR, MMM$50K
Filing ↗ - QUEST DIAGNOSTICS INCORPORATEDQUEST DIAGNOSTICS INCORPORATED · 2026 Q3 · BUD, HCR, MMM$300K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCQUEST DIAGNOSTICS · 2026 Q3 · HCR, MMM, BUD$60K
Filing ↗ - RED+BLUE STRATEGIESQUEST DIAGNOSTICS INCORPORATED · 2026 Q3 · HCR$80K
Filing ↗ - FEDERAL STREET STRATEGIES, LLCQUEST DIAGNOSTICS INCORPORATED · 2026 Q2 · HCR, MMM$50K
Filing ↗
Government Contracts
Federal awards to quest diagnostics · USAspending
$177.5MAwarded · 263 contracts on record
- Court Services and Offender Supervision AgencyRSC LAB TEST SERVICES IN FY22$48
Sep 29, 2022 · ↗ - Department of Health and Human ServicesNHDP172 C 7569 BPA CALL(S): LABORATORY TESTING SERVICES$144K
Sep 29, 2026 · ↗ - Department of Health and Human ServicesNHDP172 C 6286 LAB TEST BPA CALL ORDER$144K
Sep 29, 2025 · ↗ - Department of Health and Human ServicesNATIONWIDE CLINICAL LABORATORY TESTING SERVICES NHDP172 C 4657$144K
Sep 29, 2023 · ↗ - Department of Health and Human ServicesNATIONWIDE CLINICAL LABORATORY TESTING SERVICES NHDP172 C 4657$57K
May 22, 2023 · ↗ - Department of Health and Human ServicesNATIONWIDE CLINICAL LABORATORY TESTING SERVICES NHDP172 C 4366$87K
Sep 29, 2022 · ↗ - Department of Health and Human ServicesNATIONWIDE CLINICAL LABORATORY TESTING SERVICES NHDP172 C 3585$17K
Sep 29, 2021 · ↗ - Department of Health and Human ServicesNATIONWIDE CLINICAL LABORATORY TESTING SERVICES NHDP172 C 5297$144K
Sep 29, 2024 · ↗
U.S. Patents
Recent USPTO applications naming QUEST DIAGNOSTICS INC
No USPTO patent applications found for QUEST DIAGNOSTICS INC.
Annual Financials
From DGX's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Operating income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B |
| Net income | $992.0M | $871.0M | $854.0M | $946.0M | $2.00B |
| Diluted EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Operating cash flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B |
| Cash and equivalents | $420.0M | $549.0M | $686.0M | $315.0M | $872.0M |
| Total assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B |
| Shareholders' equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B |
As QUEST DIAGNOSTICS INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitJun 21, 2005
- 2-for-1Stock splitJun 1, 2001
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsOct 22, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsOct 22, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeOct 6, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 23, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 21, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementMay 8, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 1, 2026
EDGAR ↗
About QUEST DIAGNOSTICS INC
From SEC EDGAR company records
Industry (SIC 8071)Services-Medical Laboratories
SectorHealthcare
HeadquartersSECAUCUS, NJ
IncorporatedDE
SEC CIK0001022079 ↗
Former namesCORNING CLINICAL LABORATORIES INC








